ExploreWatchlistsPricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. Depreciation & amortization

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥4.6B
P/E ratio
-3.7x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndDepreciation & amortization (Million JPY)YoY (%)
Mar 31, 20240-97.64%
Mar 31, 202317-52.40%
Mar 31, 202235-47.33%
Mar 31, 202167+6.75%
Mar 31, 202062-24.52%
Mar 31, 201983+13.06%
Mar 31, 201873+74.58%
Mar 31, 201742+117.24%
Mar 31, 201619+119.31%
Mar 31, 20159

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat